Astellas Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Pharma sits in the top decile of US sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count).
Astellas Pharma: 165 sponsored US clinical trials, 2 recruiting.
Astellas Pharma sponsors 165 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 143 completed. 47 of these trials are in Phase 3-4 (later-stage) and 113 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Candidemia, with 4 trials.
Top-decile sponsor footprint
Astellas Pharma ranks in the top decile of sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
143 of 162 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
165 total, page 3 of 4
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
NCT01029015
A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers
NCT01476800
A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
NCT00333112
Phase 1 Study of OSI-930 in Cancer Patients
NCT00513851
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
NCT00818480
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
NCT00285259
A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis
NCT00293917
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
NCT00281541
Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation
NCT00281554
A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
NCT00116103
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
NCT00113269
A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00106392
Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy
NCT00104338
A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis
NCT00106496
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
NCT00105144
Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis
NCT00667056
Community Based Trial for AMEVIVE®
NCT00168753
A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
NCT00087724
Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
NCT00115791
Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
NCT00463541
Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
NCT00454740
Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery
NCT00125320
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
NCT00157014
A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
NCT00454896
YM443 in Subjects With Functional Dyspepsia
NCT00102310
A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients
NCT00282256
AMEVIVE® Pregnancy Registry
NCT00342862
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients
NCT00282230
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
NCT00673556
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
NCT00659412
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
NCT00674063
Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients
NCT00064701
Assessment and Tracking of Long-term Alefacept Safety
NCT00454701
A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients
NCT00282243
Optimizing Prograf® Therapy in Renal Transplant Patients
NCT00297765
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
NCT00106288
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU
NCT00048750
CP-461 in the Treatment of Patients With Advanced Melanoma
NCT00060710
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis
NCT00666159
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis
NCT00667160
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
NCT00047827
Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
NCT00047814
A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis
NCT00666302
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
NCT00046800
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
NCT00046787
A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients
NCT00282568
CP-461 for the Treatment of Crohn's Disease
NCT00042055
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
NCT00036257
Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis
NCT00036153
Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea
NCT00036192
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 59 |
| Phase 2 | 54 |
| Phase 3 | 28 |
| Phase 4 | 19 |
Therapeutic Areas
What is open in the Astellas Pharma pipeline
2 recruiting of 165 indexed (1% open); 143 completed (87%).
Phase mix: 47 late (III/IV) vs 113 early (I/II) (early-phase heavy).
Top condition: Candidemia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Pharma: open-pipeline peers nationwide
Peers matched on 165 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Astellas Pharma sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 165 trials (± recruiting share)
- Teva Branded Pharmaceutical Products R&D · 167 trials · 4% recruiting
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
Sponsors near 1% open enrollment (± trial volume)
- University of New Mexico · 1% recruiting · 168 trials
- Abbott Nutrition · 1% recruiting · 89 trials
- Baxalta now part of Shire · 1% recruiting · 74 trials
- Power Life Sciences · 2% recruiting · 62 trials
Related
What to do with this Astellas Pharma page
165 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma or any single study.
- 2 of Astellas Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Candidemia is the condition Astellas Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Candidemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astellas Pharma pipeline card: 165 registered trials from official public datasets.Report a data error.